4.8 Article

Targeting bivalency de-represses Indian Hedgehog and inhibits self-renewal of colorectal cancer-initiating cells

Journal

NATURE COMMUNICATIONS
Volume 10, Issue -, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41467-019-09309-4

Keywords

-

Funding

  1. National Research Fund
  2. Marie Curie Actions of the European Commission (FP7-COFUND)
  3. CIHR [FRN-125792]
  4. U.S. National Institutes of Health [R01CA218600, R01CA230854, R01GM122749, R01HD088626]
  5. AbbVie [1097737]
  6. Bayer Pharma AG
  7. Boehringer Ingelheim
  8. Canada Foundation for Innovation
  9. Eshelman Institute for Innovation
  10. Genome Canada through Ontario Genomics Institute [OGI055]
  11. Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant] [115766]
  12. Janssen
  13. Merck KGaA
  14. Darmstadt, Germany
  15. MSD
  16. Novartis Pharma AG
  17. Ontario Ministry of Research, Innovation and Science (MRIS)
  18. Pfizer
  19. Sao Paulo Research Foundation-FAPESP
  20. Takeda
  21. Wellcome Trust

Ask authors/readers for more resources

In embryonic stem cells, promoters of key lineage-specific differentiation genes are found in a bivalent state, having both activating H3K4me3 and repressive H3K27me3 histone marks, making them poised for transcription upon loss of H3K27me3. Whether cancer-initiating cells (C-ICs) have similar epigenetic mechanisms that prevent lineage commitment is unknown. Here we show that colorectal C-ICs (CC-ICs) are maintained in a stem-like state through a bivalent epigenetic mechanism. Disruption of the bivalent state through inhibition of the H3K27 methyltransferase EZH2, resulted in decreased self-renewal of patient-derived C-ICs. Epigenomic analyses revealed that the promoter of Indian Hedgehog (IHH), a canonical driver of normal colonocyte differentiation, exists in a bivalent chromatin state. Inhibition of EZH2 resulted in de-repression of IHH, decreased self-renewal, and increased sensitivity to chemotherapy in vivo. Our results reveal an epigenetic block to differentiation in CC-ICs and demonstrate the potential for epigenetic differentiation therapy of a solid tumour through EZH2 inhibition.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available